We demonstrated similar effects in MM and DLBCL cells using RSL3, a small molecule inhibitor that directly inhibits GPX4 by binding to the catalytic selenocysteine residue of the enzyme (Figure 1A). Here, GPX4 is linked to diffuse large B-cell lymphoma.